Hikma v. Amarin: The Supreme Court Weighs the Future of "Skinny Labeling" for Generic Drugs

The Case at a Glance

The U.S. Supreme Court is currently hearing oral arguments in Hikma v. Amarin, a pivotal case that could reshape the landscape of affordable generic medications.

At the heart of the dispute is a practice known as "skinny labeling," which allows generic drug manufacturers to sell a drug for uses that are no longer protected by patents—even when the brand-name drug still holds patents for other, separate uses.

Background: The Vascepa Story

Amarin holds patents for Vascepa, a fish oil derivative, for two distinct patient groups:

• Very high-risk heart disease patients (patent expired)
• Lower-risk patients (patent still active)

After the high-risk patent expired, Hikma received FDA approval to sell a generic version for that use only. However, Amarin sued, arguing that Hikma's marketing—particularly describing the product as a "generic version" of Vascepa without specifying the approved use—encouraged doctors to prescribe it for the still-patented, lower-risk group.

A federal circuit court sided with Amarin. Now, the Supreme Court will decide.

The Arguments

Supporting Hikma (the generic manufacturer)

"The skinny label pathway cannot function as Congress intended if a generic manufacturer's anodyne descriptions of its product create a serious risk of massive patent liability." — Trump administration's solicitor general

More than 70 legal scholars argue that Hikma's actions fall within routine marketing practices. University of Alabama law professor Sean Tu warns that a ruling for Amarin would increase legal risk for generic makers, potentially leading to longer brand monopolies and higher drug prices.

Supporting Amarin (the brand-name manufacturer)

Amarin contends that generic companies should not be allowed to market products in ways that indirectly infringe on still-patented uses. They argue this practice reduces incentives for brand companies to discover new uses for existing drugs, ultimately stifling innovation.

The Stakes: What a Ruling Could Mean

If the Court rules for Amarin:

Experts say generic manufacturers may become less willing to use skinny labeling, potentially delaying cheaper generic drugs. The stakes are enormous:

Skinny labeling allowed a generic version of Crestor to launch in 2016—six years before patents expired—saving patients and insurers over $8 billion in one year alone.

If the Court rules for Hikma:

The immediate impact on drug prices may be minimal, but the scope of the ruling could shape future use of skinny labeling for decades to come.

Expert Predictions

Experts are cautious, but note important context:

• The Supreme Court overturns lower court decisions about 70% of the time
• The Court recently ruled on another patent case, indicating a high bar for proving inducement of infringement

The final decision could be broad or narrow, with consequences rippling through the pharmaceutical industry and the healthcare system at large.